4.5 Article

Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

期刊

INFLAMMATORY BOWEL DISEASES
卷 29, 期 5, 页码 830-833

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izac164

关键词

ulcerative colitis; Crohn's disease; inflammatory bowel disease; ustekinumab; loss of response; dose escalation; optimization

向作者/读者索取更多资源

In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.
Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据